Efficacy and tolerability of recombinant human erythropoietin treatment in pre-dialysis patients: results of a multicenter study

International Journal of Artificial Organs

Volumn 21, Issue 1, 1998, Pages 12-18

  Albertazzi, A ^a,c   Di Liberato, L ^a   Daniele, F ^a   Battistel, V ^b   Colombi, L ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b Boehringer Mannheim Italia   (Italy)

^c SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

Author keywords

Anemia; Chronic renal failure; rHu EPO treatment

Indexed keywords

BLOOD PRESSURE; BODY FLUIDS; PATIENT TREATMENT;

ANEMIA; CHRONIC RENAL FAILURE; HUMAN ERYTHROPOIETIN; LOW DOSE; MULTI-CENTRE STUDY; PRE-TREATMENTS; PRESSURE VALUES; PROSPECTIVES; RECOMBINANT HUMAN ERYTHROPOIETIN TREATMENT; RENAL FUNCTIONS;

DIALYSIS;

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ANALGESIC NEPHROPATHY; ANEMIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD TRANSFUSION; CHRONIC KIDNEY FAILURE; CLINICAL TRIAL; DIABETIC NEUROPATHY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; FEMALE; GLOMERULONEPHRITIS; GLOMERULUS FILTRATION; HEMODIALYSIS PATIENT; HEMOGLOBIN DETERMINATION; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY FAILURE; KIDNEY POLYCYSTIC DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEPHROSCLEROSIS; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0031910661     PISSN: 03913988     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Abraham PA, Opsahl JA, Rachael KM, Asinger R, Halstenson CE. Renal function during erythropoietin therapy for anemia in predialysis chronic renal failure patients. Am J Nephrol 1990; 10: 128-36.
2. Watson AJ, Gimenez LF, Cotton S, Walser M, Spivak JL Treatment of the anemia of chronic renal failure with subcutaneous recombinant human erythropoietin. Am J Med 1989; 89: 432-5.
3. Kentera PV, Clemans GK, Djukanovic L, Paunovic LB. Erythropoietin and Anemia in Chronic Renal Failure. Exp Hematol 1987; 15: 785-9.
4. McGonigle RJS, Wallin JD, Shadduck RK, Fisher JW. Erythropoietin deficiency and inhibition of erythropoiesis in renal insufficiency. Kidney Int 1984; 25: 437-44.
5. Brendan PT et al. Double-blind, placebo-controlled study of the therapeutic use of recombinant human erythropoietin for anemia associated with chronic renal failure in pre-dialysis patients. Am J Kidney Dis 1991; 18: 50-9.
6. Kleinman KS, Schweitzer SU, Perduc ST, Bleifer KH, Abels RI. The use of recombinant human erythropoietin in the correction of anemia in predialysis patients and its effect on renal function: a double-blind placebo-controlled trial. Am J Kidney Dis 1989; 14: 486-95.
7. Eschbach JW, Adamson JW: Anemia of ESRD (Editorial Review). Kidney Int 1985, 28: 1-5.
8. Eschbach J, Egrie JC, Downing R et al. Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73-8.
9. Koene RAP, Frenken LAM. Role of rHu-EPO in treatment of uremic anemia prior to end-stage renal disease. Kidney Int 1992; 42: S-142-7.
10. Garcia DL, Anderson S, Renuke HG et al. Anemia lessons and its prevention with recombinant human erythropoietin worsens glomerular injury and hypertension in rats with reduced renal mass. Proc Natl Acad Sci USA 1988; 85: 6142-6
11. Postorino M, Martorano C, Salnitro F, Zoccali C. Il "breakpoint" test, un nuovo metodo statistico per lo studio della progressione della insufficienza renale cronica. Giorn It Nefrol 1988; 4: 251-5.
12. Anderson S. Effects of erythropoietin in predialysis patients. Am J Kidney Dis 1991; 5 (suppl 1), 103-6.
13. Casati S, Passerini P, Campise MR, et al. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017-20.
14. Eschbach JW, Downing MR, Egrie JC, Browne JK, Adamson W. USA multicenter clinical trial with recombinant human erythropoietin (Amgen). Contrib Nephrol Basel, Karger 1989; 76: 160-5.
15. Sobota JT. Recombinant human erythropoietin in patients with anemia due to end-stage renal disease. Contrib Nephrol Basel, Karger 1989; 76: 166-78.
16. Buccianti G, Colombi L, Battistel V. Use of recombinant erythropoietin (rhu-EPO) in the treatment of anemia in hemodialysis patients: a multicenter Italian experience. Haematologica: 1993; 78: 111-7.
17. Zins B, Drueke T, Zingraff J. Erythropoietin treatment in anemic patients on hemodialysis. Lancet 1986; 2: 1329.
18. Lim VS, De Godwin RL, Zavala D et al. Recombinant human erythropoietin treatment in pre-dialysis patients. Ann Intern Med 1989; 110: 108-14.
19. Frenken LAM, Verbeckmoes R, Michielsen P, Koene RAP. Efficacy and tolerance of treatment with recombinant human erythropoietin in chronic renal failure (pre-dialysis) patients. Nephrol Dial Transpl 1989; 4: 782-6.
20. Brown CD, Friedman EA. Clinical and blood rheologic stablity in erythropoietin-treated predialysis patients. Am J Nephrol 1990; 10 (suppl.2): 29-33.
21. Anastassiades E, Howarth D, Howarth J, Shanks D et al. Influence of blood volume on the blood pressure of predialysis and peritoneal dialysis patients treated with erythropoietin. Nephrol Dial Transpl 1993; 8: 621-5.
22. Di Paolo B, Di Liberato L, Albertazzi A et al. Effects of uremia and dialysis on brain electrophysiology after recombinant erythropoietin treatment. ASAIO J 1992; 38: M477-80.
23. Austrian Multicenter Study Group of r-HuEPO in Predialysis Patients: Effectiveness and safety of recombinant human erythropoietin in predialysis patients. Nephron 1992; 61: 398-403.
24. Bommer J, Barth HP, Zeier M et al. Efficacy comparison of intravenous and subcutaneous recombinant human erythropoietin administration in hemodialysis patients. Contrib Nephrol 1991; 88: 136-43.
25. Editorial. The subcutaneous administration route of epoetin: advantages, pain at the injection site and patient acceptance, Int J Artrf Organs 1993; 161-3.
26. Boelaret JR, Schurgers ML, Matthys EG et al. Comparative pharmacokinetics of recombinant erythropoietin administered by the intravenous, subcutaneous and intraperitoneal routes in continuous, ambulatory peritoneal dialysis (CARD) patients. Perit Dial Bull 1989; 9: 95-8.
27. Zappacosta AR, Perras ST, Bell A. Weekly subcutaneous recombinant human erythropoietin corrects anemia of progressive renal failure. Am J Med 1991; 91: 229-32.
28. Mitch WE, Walser M, Buffington GA, Lameire J. A simple method for estimating progression of chronic renal failure. Lancet 1976; 2: 1326-8.